Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for KALETRA
- The Role of Home Packs of HIV PEPSE in High Risk Individuals
- Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
- FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
- DEFINE - Evaluating Therapies for COVID-19
- Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
- Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia
- Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
- Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions
- Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
- Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
- Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
- The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection
- Umifenovir in Hospitalized COVID-19 Patients
- Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
- COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
- Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Test Albuvirtide in Experienced Patients
- Early Infant HIV Treatment in Botswana
- Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects
- Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication
- Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized,
- Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
- LAAM-HAART PET Imaging
- IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
- Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
- Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
- Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
- Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women
- Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
- Post-Exposure Prophylaxis in Health Care Workers
- Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
- Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
- KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (
- PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
- A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
- Effects of Intensive cART During Acute/Early HIV Infection
- Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
- Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa
- Evaluation of Kaletra Therapy Over the Long-term
- Special Investigation of Kaletra in Pregnant Women
- Drug Use Investigation of Kaletra
- Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
- Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
- Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
- Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
- A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
- Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
- Ritonavir-boosted Lopinavir Monotherapy
- Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
- The Maraviroc Central Nervous System (CNS) Study
- Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
- Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
- IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
- Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
- Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
- Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
- Dose Reduction of Lopinavir in Children
- Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
- GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
- Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
- Lopinavir/Ritonavir (Kaletra) PK in Children
- TDM of Generic Lopinavir/Ritonavir 200/50 mg
- Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
- ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
- An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
- The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
- NNRTI/PI Toxicity Switch to Darunavir Study
- Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- GSK706769/KALETRA Drug-drug Interaction Study
- Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
- Kaletra-isentress Treatment Evaluation
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations
- Kaletra and Viread in Antiretroviral Naïve Patients
- Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)
- Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients
- Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
- Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
- Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
- Clinical Trial of CNS-targeted HAART (CIT2)
- Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
- Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
- Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy
- Relationship Between HIV-1 Subtype and ARV Response
- Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
- Raltegravir Kaletra Pharmacokinetics
- HIV - Monotherapy in Switzerland (MOST-ch)
- Kaletra Monotherapy in HIV/HCV Co-infected Subjects
- Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil
- MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)
- MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)
- Lopinavir Capsules to Kaletra or Invirase Tablets
- Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
- Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
- BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
- Metabolic Effects of Switching Kaletra to Boosted Reyataz
- FREE Study: Efficacy and Toxicity of Trizivir
- The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients
- Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
- Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Su
- Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
- Antiretroviral Therapy for Advanced HIV Disease in South Africa
- Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients
- To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir
- Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
- BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
- TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
- High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease
- Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
- Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
- Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy
- Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients
- Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
- Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
- Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients
- Induction-maintenance of Lopinavir/r in HIV-infected Subjects
- A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
- Kaletra Sex/Gender Pharmacokinetics (PK) Study
- A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
- NRTI-Sparing Pilot Study
- A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
- Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients
- "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
- TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
- GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
- GW873140 In Combination With Kaletra In HIV Infected Subjects
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
- KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
- The Effect of Lopinavir/Ritonavir on Endothelial Function
- A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- Antihyperlipidemic Effects of Oyster Mushrooms
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
- Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
- Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children
- ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
Clinical trials list
click for details